http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2018371550-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4d5de9a1dac6b033c4643bb236ef4df3 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6886 |
| filingDate | 2016-07-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cb2136d780bae0a8f19de634c52f4e09 |
| publicationDate | 2018-12-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2018371550-A1 |
| titleOfInvention | Loss of transcriptional fidelity leads to immunotherapy resistance in cancers |
| abstract | Methods and compositions disclosed herein generally relate to determining suitability of immunotherapy for a subject having cancer, by determining whether tumor cells from a subject having cancer or one or more symptoms thereof have a loss of transcriptional fidelity (LTF) phenotype. Embodiments of the invention relate to methods of stratifying one or more subjects in a clinical trial by determining whether tumor cells from one or more subjects having cancer or one or more symptoms thereof have an LTF phenotype. Embodiments of the invention also relate to diagnostic kits, tests, or arrays to test for presence of a loss of transcriptional fidelity (LTF) phenotype in a sample. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11035858-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021113773-A3 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021019526-A1 |
| priorityDate | 2015-07-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 2315.